This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
acute respiratory | 204 |
respiratory syndrome | 133 |
severe acute | 131 |
novel coronavirus | 131 |
coronavirus disease | 126 |
immune response | 122 |
lung injury | 106 |
immune system | 105 |
respiratory distress | 97 |
converting enzyme | 97 |
severe covid | 95 |
cytokine storm | 93 |
spike protein | 93 |
med hypotheses | 91 |
doc id | 87 |
hypotheses doi | 87 |
cord uid | 87 |
oxidative stress | 82 |
distress syndrome | 80 |
syndrome coronavirus | 79 |
endothelial cells | 75 |
epithelial cells | 61 |
inflammatory cytokines | 60 |
immune cells | 58 |
innate immune | 54 |
nitric oxide | 46 |
viral infection | 46 |
inflammatory response | 45 |
immune responses | 44 |
viral infections | 42 |
acute lung | 42 |
clinical characteristics | 42 |
virus infection | 41 |
risk factors | 41 |
hydrogen peroxide | 40 |
host cells | 40 |
influenza virus | 39 |
ace receptor | 38 |
critically ill | 38 |
clinical trials | 38 |
may also | 37 |
respiratory tract | 36 |
endothelial dysfunction | 35 |
systematic review | 33 |
cardiovascular disease | 32 |
viral load | 32 |
angiotensin ii | 32 |
endothelial cell | 31 |
blood group | 30 |
air pollution | 30 |
intensive care | 30 |
ang ii | 30 |
patients infected | 30 |
ill patients | 29 |
host cell | 29 |
public health | 29 |
angiotensin system | 29 |
inflammatory cytokine | 29 |
vascular endothelial | 28 |
angiotensin converting | 28 |
innate immunity | 28 |
sars coronavirus | 28 |
east asia | 28 |
type diabetes | 27 |
infected patients | 26 |
important role | 26 |
clinical course | 26 |
necrosis factor | 26 |
severe cases | 26 |
viral replication | 26 |
diabetes mellitus | 25 |
lung inflammation | 25 |
cell entry | 25 |
binding protein | 25 |
abo blood | 25 |
coronavirus pneumonia | 24 |
new coronavirus | 24 |
hospitalized patients | 24 |
nlrp inflammasome | 24 |
authors declare | 24 |
tumor necrosis | 24 |
blood vessels | 23 |
human coronavirus | 23 |
alveolar epithelial | 23 |
bcg vaccination | 23 |
inflammatory responses | 22 |
side effects | 22 |
nuclear factor | 22 |
type i | 22 |
infectious diseases | 22 |
corona virus | 22 |
vascular thrombosis | 21 |
surface tension | 21 |
valproic acid | 21 |
cell surface | 21 |
adaptive immune | 21 |
world health | 21 |
ocular surface | 21 |
health organization | 21 |
proinflammatory cytokines | 20 |
oxygen species | 20 |
reactive oxygen | 20 |
viral entry | 20 |
cell signaling | 20 |
adipose tissue | 20 |
clinical features | 19 |
vascular endothelium | 19 |
type ii | 19 |
nervous system | 19 |
inflammatory mediators | 19 |
serine protease | 19 |
induced lung | 19 |
pulmonary surfactant | 18 |
dendritic cells | 18 |
potential therapeutic | 18 |
increased risk | 18 |
mortality rate | 18 |
high risk | 18 |
pulmonary surfactants | 18 |
liquid crystalline | 18 |
million people | 18 |
disease severity | 18 |
cell death | 18 |
severe disease | 18 |
control measures | 18 |
mechanical ventilation | 17 |
clinical trial | 17 |
high levels | 17 |
may lead | 17 |
stem cells | 17 |
alveolar cells | 17 |
mesenchymal stem | 17 |
ace ace | 17 |
cytokine production | 17 |
pulmonary disease | 17 |
united states | 17 |
growth factor | 17 |
systemic inflammation | 17 |
coronavirus infection | 17 |
protein kinase | 17 |
sars cov | 17 |
may cause | 17 |
respiratory failure | 16 |
ace expression | 16 |
male reproductive | 16 |
male patients | 16 |
cov infection | 16 |
hong kong | 16 |
rheumatoid arthritis | 16 |
receptor binding | 16 |
cytokine release | 16 |
crystalline phase | 16 |
blood cells | 16 |
risk factor | 16 |
receptor ace | 15 |
heart failure | 15 |
blood pressure | 15 |
rna viruses | 15 |
human ace | 15 |
upper respiratory | 15 |
liver injury | 15 |
singlet oxygen | 15 |
infected cells | 15 |
sialic acid | 15 |
blood coagulation | 15 |
also known | 15 |
health care | 15 |
infected people | 15 |
cell proliferation | 15 |
respiratory system | 15 |
phase transition | 15 |
central nervous | 15 |
cell types | 15 |
cell lines | 15 |
mount etna | 15 |
surface viscosity | 15 |
hpa axis | 15 |
night shift | 15 |
respiratory infections | 14 |
organ failure | 14 |
suppressor cells | 14 |
peripheral blood | 14 |
heavy metals | 14 |
adaptive immunity | 14 |
observational study | 14 |
neutrophil extracellular | 14 |
medical staff | 14 |
endothelial damage | 14 |
respiratory diseases | 14 |
endothelial function | 14 |
coronavirus infections | 14 |
extracellular traps | 14 |
metabolic syndrome | 14 |
expressing cells | 14 |
protease inhibitor | 14 |
clinical studies | 14 |
randomized controlled | 14 |
spike glycoprotein | 13 |
icu patients | 13 |
middle east | 13 |
viral spike | 13 |
microvascular thrombosis | 13 |
signaling pathway | 13 |
binding domain | 13 |
drug interactions | 13 |
laden macrophages | 13 |
septic shock | 13 |
shift work | 13 |
severe forms | 13 |
lipid metabolism | 13 |
organ dysfunction | 13 |
neutrophil elastase | 13 |
peroxisome proliferator | 13 |
lung damage | 13 |
cohort study | 13 |
blood clots | 13 |
cd mdsc | 13 |
infectious disease | 13 |
protective effect | 13 |
respiratory disease | 13 |
pulmonary edema | 13 |
activated receptor | 13 |
personal relationships | 13 |
care unit | 13 |
animal models | 13 |
thrombin generation | 13 |
inflammatory effects | 13 |
macrophage activation | 13 |
high mortality | 13 |
global health | 13 |
new york | 13 |
allium sativum | 13 |
crucial role | 13 |
relative humidity | 13 |
burnout syndrome | 13 |
central europe | 12 |
chronic obstructive | 12 |
infectious agents | 12 |
infected pneumonia | 12 |
th cells | 12 |
antiviral activity | 12 |
host immune | 12 |
mobility group | 12 |
bone marrow | 12 |
drug delivery | 12 |
highly expressed | 12 |
murine models | 12 |
case series | 12 |
known competing | 12 |
several studies | 12 |
coagulation cascade | 12 |
older adults | 12 |
receptor expression | 12 |
coronavirus spike | 12 |
thrombotic complications | 12 |
competing financial | 12 |
cytokine secretion | 12 |
social distancing | 12 |
fine pm | 12 |
well known | 12 |
pathological findings | 12 |
may play | 12 |
ace receptors | 12 |
poor prognosis | 12 |
severe sars | 12 |
recent study | 12 |
key role | 12 |
associated lung | 12 |
ace deficiency | 12 |
elevated levels | 12 |
syncytial virus | 11 |
immunodeficiency virus | 11 |
carbohydrate interactions | 11 |
kidney disease | 11 |
china clinical | 11 |
higher risk | 11 |
viral rna | 11 |
high mobility | 11 |
systemic inflammatory | 11 |
alveolar type | 11 |
respiratory droplets | 11 |
tobacco mosaic | 11 |
also reported | 11 |
east respiratory | 11 |
hyperinflammatory response | 11 |
consumptive coagulopathy | 11 |
lung tissue | 11 |
higher mortality | 11 |
preterm labor | 11 |
fatality rate | 11 |
early stage | 11 |
activated charcoal | 11 |
financial interests | 11 |
venous thromboembolism | 11 |
gc protein | 11 |
qt interval | 11 |
ace expressing | 11 |
lymphatic vessels | 11 |
protease tmprss | 11 |
willebrand factor | 11 |
severe respiratory | 11 |
ebola virus | 11 |
human immunodeficiency | 11 |
simplex virus | 11 |
cell exhaustion | 11 |
testosterone levels | 11 |
herpes simplex | 11 |
tissue factor | 11 |
icu admission | 11 |
ill covid | 11 |
inhibitory effect | 11 |
particulate matter | 11 |
lung disease | 11 |
inflammatory state | 11 |
higher levels | 11 |
platelet aggregation | 11 |
obstructive pulmonary | 11 |
entry receptor | 11 |
mosaic virus | 11 |
reproductive function | 11 |
pulmonary vascular | 11 |
respiratory syncytial | 11 |
oral mucosa | 10 |
european countries | 10 |
alveolar damage | 10 |
smooth muscle | 10 |
mortality rates | 10 |
lymphatic system | 10 |
alveolar macrophages | 10 |
factors associated | 10 |
case fatality | 10 |
wide range | 10 |
entry depends | 10 |
knockout mice | 10 |
blood flow | 10 |
plasma membrane | 10 |
staphylococcus aureus | 10 |
free dna | 10 |
severe stages | 10 |
target cells | 10 |
derived suppressor | 10 |
membrane fusion | 10 |
multiple organ | 10 |
work reported | 10 |
activating factor | 10 |
intraalveolar lipid | 10 |
von willebrand | 10 |
may result | 10 |
medical residents | 10 |
exhaled breath | 10 |
pregnant women | 10 |
adverse effects | 10 |
transcription factor | 10 |
clinically proven | 10 |
convalescent plasma | 10 |
tissue damage | 10 |
cell infection | 10 |
reductase inhibitors | 10 |
tissue injury | 10 |
tlr activation | 9 |
clinical outcomes | 9 |
squamous cell | 9 |
currently available | 9 |
exogenous surfactant | 9 |
small intestine | 9 |
line tension | 9 |
cell culture | 9 |
release syndrome | 9 |
hmgb antibodies | 9 |
activated protein | 9 |
randomized clinical | 9 |
east asian | 9 |
proven protease | 9 |
gene expression | 9 |
extracellular matrix | 9 |
liver disease | 9 |
respiratory viral | 9 |
group box | 9 |
high expression | 9 |
main protease | 9 |
clinical symptoms | 9 |
receptor antagonist | 9 |
may contribute | 9 |
cystic fibrosis | 9 |
safety profile | 9 |
cd cells | 9 |
inflammatory effect | 9 |
respiratory symptoms | 9 |
deleterious effects | 9 |
phase separation | 9 |
clinical data | 9 |
stranded rna | 9 |
ace activity | 9 |
renal function | 9 |
pulmonary fibrosis | 9 |
cell membrane | 9 |
infection may | 9 |
diabetic patients | 9 |
trained immunity | 9 |
fine particulate | 9 |
therapeutic strategies | 9 |
shift workers | 9 |
lithium chloride | 9 |
lower respiratory | 9 |
mild symptoms | 9 |
garlic extract | 9 |
viral components | 9 |
reactive protein | 9 |
oral cancer | 9 |
plasminogen activator | 9 |
controlled trials | 9 |
ncov infection | 9 |
mevalonate pathway | 9 |
rna virus | 9 |
retrospective cohort | 9 |
reproductive system | 9 |
extrahepatic vitamin | 9 |
increased mortality | 9 |
angiotensin i | 9 |
face masks | 9 |
chinese herbal | 9 |
specific antibodies | 9 |
immune fitness | 8 |
functional receptor | 8 |
coronavirus nl | 8 |
like receptor | 8 |
previous studies | 8 |
severely ill | 8 |
severe symptoms | 8 |
also found | 8 |
family history | 8 |
protective equipment | 8 |
east asians | 8 |
mesentery fat | 8 |
inflammatory storm | 8 |
metabolizing enzymes | 8 |
signaling pathways | 8 |
taurine chloramine | 8 |
care workers | 8 |
transmembrane protease | 8 |
traditional chinese | 8 |
may explain | 8 |
influenza viruses | 8 |
serum albumin | 8 |
potential role | 8 |
natural killer | 8 |
diabetic nephropathy | 8 |
enzyme activity | 8 |
infected individuals | 8 |
chronic exposure | 8 |
regulating autophagy | 8 |
inflammatory properties | 8 |
observational studies | 8 |
serum levels | 8 |
case report | 8 |
myocardial infarction | 8 |
cell apoptosis | 8 |
inflammasome pathway | 8 |
blood clotting | 8 |
covid virus | 8 |
cell carcinoma | 8 |
protein fragment | 8 |
relatively high | 8 |
fatty acid | 8 |
tract infections | 8 |
york city | 8 |
air quality | 8 |
hemorrhagic consumptive | 8 |
new cases | 8 |
dry cough | 8 |
associated molecular | 8 |
retrospective study | 8 |
significant increase | 8 |
therapeutic agent | 8 |
invasive ventilation | 8 |
aat inhibits | 8 |
asian countries | 8 |
surfactant protein | 8 |
lung epithelial | 8 |
oxide synthase | 8 |
hospitalized covid | 8 |
pulmonary system | 8 |
amino acid | 8 |
high concentration | 8 |
protease enzyme | 8 |
cov spike | 8 |
chronic kidney | 8 |
adult inpatients | 8 |
sars patients | 8 |
cytokines il | 8 |
serum testosterone | 8 |
lung pathology | 8 |
healthy subjects | 8 |
free area | 8 |
death rate | 8 |
muscle cells | 8 |
skeletal muscle | 8 |
respiratory virus | 8 |
virus particles | 8 |
fatty acids | 8 |
circadian rhythms | 8 |
long term | 8 |
nk cells | 8 |
signalling pathways | 8 |
oral squamous | 7 |
aldosterone system | 7 |
human vascular | 7 |
injury induced | 7 |
endothelial injury | 7 |
coronavirus sars | 7 |
glutathione levels | 7 |
treg th | 7 |
red blood | 7 |
lung function | 7 |
glucose metabolism | 7 |
cardiac injury | 7 |
severe lung | 7 |
high concentrations | 7 |
gases emitted | 7 |
study showed | 7 |
years old | 7 |
may affect | 7 |
droplet size | 7 |
redox status | 7 |
high level | 7 |
inflammatory cells | 7 |
mediated cell | 7 |
older people | 7 |
cell cultures | 7 |
high prevalence | 7 |
intestinal permeability | 7 |
bat origin | 7 |
patients may | 7 |
pneumonia outbreak | 7 |
dendritic cell | 7 |
monoclonal antibody | 7 |
drug interaction | 7 |
new therapeutic | 7 |
storm syndromes | 7 |
male reproduction | 7 |
probable bat | 7 |
product use | 7 |
structural basis | 7 |
induced oxidative | 7 |
interferon response | 7 |
cells may | 7 |
enveloped virus | 7 |
pivotal role | 7 |
like receptors | 7 |
visceral adipose | 7 |
lateral phase | 7 |
gastrointestinal tract | 7 |
clinical manifestations | 7 |
diffuse alveolar | 7 |
herbal remedies | 7 |
ace inhibitors | 7 |
physical activity | 7 |
respiratory infection | 7 |
inflammation induced | 7 |
glioma cells | 7 |
virus disease | 7 |
disease progression | 7 |
ii receptor | 7 |
taken together | 7 |
immune dysregulation | 7 |
blood type | 7 |
people infected | 7 |
immune function | 7 |
airborne transmission | 7 |
coronary artery | 7 |
cu ions | 7 |
cell injury | 7 |
free cholesterol | 7 |
abnormal coagulation | 7 |
outbreak associated | 7 |
progenitor cells | 7 |
macrophage activating | 7 |
poor outcomes | 7 |
pathological conditions | 7 |
cell line | 7 |
lung cancer | 7 |
descriptive study | 7 |
endothelial growth | 7 |
cell membranes | 7 |
consider cytokine | 7 |
endothelial nitric | 7 |
south east | 7 |
direct correlation | 7 |
molecular mechanisms | 7 |
inflammatory markers | 7 |
immune defence | 7 |
rapid spread | 7 |
human transmission | 7 |
virus rna | 7 |
global pandemic | 7 |
cell damage | 7 |
risk individuals | 7 |
leydig cells | 7 |
ventilated patients | 7 |
heart disease | 7 |
controlled trial | 7 |
first case | 6 |
circulating levels | 6 |
null allele | 6 |
first step | 6 |
hypothesis suggests | 6 |
viral particles | 6 |
active property | 6 |
worse prognosis | 6 |
another study | 6 |
cov virus | 6 |
therapeutic effect | 6 |
chronic diseases | 6 |
viral protein | 6 |
receptor blockers | 6 |
clinical study | 6 |
reproduction number | 6 |
health emergency | 6 |
disease model | 6 |
phase boundaries | 6 |
ace signaling | 6 |
mycobacterium tuberculosis | 6 |
disease caused | 6 |
human airway | 6 |
immune cell | 6 |
virus origins | 6 |
treg cells | 6 |
beneficial effects | 6 |
pathogenic role | 6 |
evans blue | 6 |
large number | 6 |
system activation | 6 |
nad levels | 6 |
elderly patients | 6 |
contact rate | 6 |
interstitial lung | 6 |
oral activated | 6 |
risk group | 6 |
significant role | 6 |
trace elements | 6 |
endoplasmic reticulum | 6 |
damage caused | 6 |
ii pneumocytes | 6 |
binding affinity | 6 |
may induce | 6 |
second outbreak | 6 |
infected persons | 6 |
highly contagious | 6 |
immunomodulatory effects | 6 |
stimulating factor | 6 |
might also | 6 |
chronic inflammatory | 6 |
cholesterol levels | 6 |
clinical evidence | 6 |
breath condensate | 6 |
affects male | 6 |
early endothelial | 6 |
nh cl | 6 |
reproductive ability | 6 |
standing potential | 6 |
although sars | 6 |
findings suggest | 6 |
neonatal respiratory | 6 |
vitro studies | 6 |
possible mechanism | 6 |
epidemic curve | 6 |
including il | 6 |
enveloped viruses | 6 |
tobacco smoking | 6 |
pulmonary inflammation | 6 |
monoclonal antibodies | 6 |
vitamin derivative | 6 |
gattii species | 6 |
unmodified vitamin | 6 |
central role | 6 |
type alveolar | 6 |
prostate cancer | 6 |
bone destruction | 6 |
widely available | 6 |
leukotriene receptor | 6 |
may provide | 6 |
infection due | 6 |
ace protein | 6 |
new drugs | 6 |
cardiovascular diseases | 6 |
cellular immune | 6 |
cryptococcus neoformans | 6 |
binding site | 6 |
induced apoptosis | 6 |
lung diseases | 6 |
hepatic cytochrome | 6 |
inducible factor | 6 |
clinical presentation | 6 |
factors related | 6 |
rat hepatocytes | 6 |
angiotensin receptor | 6 |
patients hospitalized | 6 |
superoxide dismutase | 6 |
viral respiratory | 6 |
gas exchange | 6 |
also showed | 6 |
ii cells | 6 |
airway epithelia | 6 |
general population | 6 |
high affinity | 6 |
cellular entry | 6 |
inflammasome activation | 6 |
cu deficiency | 6 |
rna polymerase | 6 |
vascular endothelialitis | 6 |
therapeutic agents | 6 |
nerve stimulation | 6 |
molecular patterns | 6 |
literature review | 6 |
financial support | 6 |
ace mediated | 6 |
coronavirus outbreak | 6 |
human cells | 6 |
essential role | 6 |
biological system | 6 |
virus infections | 6 |
benign prostatic | 6 |
cell receptor | 6 |
acetate may | 6 |
blood cell | 6 |
high altitude | 6 |
rna synthesis | 6 |
blood groups | 6 |
organ damage | 6 |
antiviral effect | 6 |
therapeutic effects | 6 |
amino acids | 6 |
coagulation parameters | 6 |
male fertility | 6 |
recent studies | 6 |
neurodegenerative diseases | 6 |
much higher | 6 |
perinasal lymphatic | 6 |
cell activation | 6 |
related coronavirus | 6 |
factor receptors | 6 |
higher prevalence | 6 |
lung fibrosis | 6 |
type interferon | 6 |
bacterial infection | 6 |
glycogen synthase | 6 |
viral clearance | 6 |
human alveolar | 6 |
also called | 6 |
low testosterone | 6 |
control group | 6 |
many studies | 6 |
mouse model | 6 |
response may | 6 |
adverse reactions | 6 |
virus replication | 6 |
excessive inflammation | 6 |
plasma levels | 6 |
relatively low | 6 |
allergic rhinitis | 6 |
high incidence | 6 |
inflammatory reaction | 6 |
hyperimmune anti | 6 |
virus binding | 6 |
human immune | 6 |
reaction product | 6 |
aat inhibition | 6 |
white blood | 6 |
i interferon | 6 |
antiviral drugs | 6 |
statin therapy | 6 |
increasing evidence | 5 |
chloroquine phosphate | 5 |
drug administration | 5 |
novel drug | 5 |
host defense | 5 |
incubation period | 5 |
driving force | 5 |
cells will | 5 |
cardiovascular cells | 5 |
covert infection | 5 |
among patients | 5 |
neutrophil infiltration | 5 |
stem cell | 5 |
early treatment | 5 |
group antibodies | 5 |
cytokine levels | 5 |
sialyl tn | 5 |
glutathione synthesis | 5 |
may facilitate | 5 |
vascular function | 5 |
higher level | 5 |
climatic conditions | 5 |
viral diseases | 5 |
neutralizing antibodies | 5 |
inflammatory protein | 5 |
antioxidative property | 5 |
receptor recognition | 5 |
study covid | 5 |
also inhibit | 5 |
severe illness | 5 |
dependent manner | 5 |
cultured human | 5 |
emmprin expression | 5 |
early stages | 5 |
greater risk | 5 |
bone resorption | 5 |
intestinal inflammation | 5 |
heightened cytokine | 5 |
critical role | 5 |
effective treatment | 5 |
respiratory disorders | 5 |
cell receptors | 5 |
may occur | 5 |
novel angiotensin | 5 |
critical care | 5 |
oral nac | 5 |
endothelial progenitor | 5 |
macrophage inflammatory | 5 |
ar signaling | 5 |
new virus | 5 |
rodent models | 5 |
ill icu | 5 |
aat deficiency | 5 |
expansion cycling | 5 |
killer cells | 5 |
renin angiotensin | 5 |
lopinavir ritonavir | 5 |
microbial components | 5 |
treatment protocols | 5 |
viral sgp | 5 |
meningeal lymphatic | 5 |
approved drugs | 5 |
major risk | 5 |
study using | 5 |
rna sequencing | 5 |
th cell | 5 |
hcq cq | 5 |
cerebral immune | 5 |
important lessons | 5 |
barrier disruption | 5 |
tobacco smoke | 5 |
clinical outcome | 5 |
surfactant administration | 5 |
virucidal activity | 5 |
tocopherol transfer | 5 |
respiratory illness | 5 |
ace ratio | 5 |
well tolerated | 5 |
lung compliance | 5 |
lipid bilayer | 5 |
theta defensins | 5 |
cells decreased | 5 |
glass opacity | 5 |
surfactant function | 5 |
viral genome | 5 |
take place | 5 |
nicotinamide adenine | 5 |
respiratory burst | 5 |
residency training | 5 |
fusion protein | 5 |
hypertonic ibuprofen | 5 |
called cytokine | 5 |
low serum | 5 |
respiratory epithelium | 5 |
close contact | 5 |
outcomes among | 5 |
proinflammatory mediators | 5 |
virus type | 5 |
reduced covid | 5 |
vascular wall | 5 |
cell recognition | 5 |
immune modulation | 5 |
human body | 5 |
personal protective | 5 |
targeted treatment | 5 |
storm syndrome | 5 |
pay attention | 5 |
viral upper | 5 |
right ventricular | 5 |
proliferator activated | 5 |
basic reproduction | 5 |
infected subjects | 5 |
administered prophylactically | 5 |
epithelial cell | 5 |
emergency unit | 5 |
central obesity | 5 |
second wave | 5 |
lung epithelium | 5 |
renal failure | 5 |
oral cavity | 5 |
length human | 5 |
several factors | 5 |
adenine dinucleotide | 5 |
blood system | 5 |
surface receptor | 5 |
early phase | 5 |
tb infections | 5 |
respiratory compression | 5 |
therapeutic potential | 5 |
even though | 5 |
lung infection | 5 |
protein priming | 5 |
human lung | 5 |
animal studies | 5 |
understanding sars | 5 |
significantly increased | 5 |
tubule cells | 5 |
surface glycoprotein | 5 |
hemorrhagic shock | 5 |
experimental studies | 5 |
medical errors | 5 |
electrical charge | 5 |
may prevent | 5 |
activation syndrome | 5 |
angiotensinconverting enzyme | 5 |
asymptomatic infection | 5 |
cascade thrombin | 5 |
transfer protein | 5 |
lower level | 5 |
influenza pandemic | 5 |
cell dysfunction | 5 |
central european | 5 |
free radicals | 5 |
maillard reaction | 5 |
cell function | 5 |
cell rna | 5 |
recycling rates | 5 |
temporal evolution | 5 |
contact parameter | 5 |
genomic characterisation | 5 |
promising therapeutic | 5 |
hpa system | 5 |
ii alveolar | 5 |
antiviral effects | 5 |
renal injury | 5 |
sectional study | 5 |
tmprss expression | 5 |
underlying mechanisms | 5 |
human respiratory | 5 |
transmission dynamics | 5 |
viral interference | 5 |
even renal | 5 |
factor ii | 5 |
sars epidemic | 5 |
activated platelets | 5 |
mdsc populations | 5 |
takes place | 5 |
vascular cells | 5 |
aerodynamic diameter | 5 |
fatal disease | 5 |
hypothesis date | 5 |
related deaths | 5 |
protease serine | 5 |
poorer prognosis | 5 |
care units | 5 |
terminal domain | 5 |
procoagulant activity | 5 |
preventive measures | 5 |
confirmed cases | 5 |
covid patients | 5 |
aerosol spray | 5 |
temperate environments | 5 |
cd rs | 5 |
oxidant stress | 5 |
epidemiological studies | 5 |
protein interaction | 5 |
among hospitalized | 5 |
receptor antagonists | 5 |
ptx dip | 5 |
data show | 5 |
mdsc cells | 5 |
zika virus | 5 |
cytokine storms | 5 |
vascular damage | 5 |
personal accomplishment | 5 |
south korea | 5 |
antiviral activities | 5 |
influenza vaccine | 5 |
herbal formulations | 5 |
bronchitis virus | 5 |
author declares | 5 |
dimensional phase | 5 |
late mediator | 5 |
better understand | 5 |
bone metabolism | 5 |
disease states | 5 |
edged sword | 5 |
surgical masks | 5 |
initial phase | 5 |
abh antigens | 5 |
increased severity | 5 |
arterial hypertension | 5 |
much lower | 5 |
higher viral | 5 |
viral loads | 5 |
smaller particles | 5 |
healthy adults | 5 |
rna genome | 5 |
also demonstrated | 5 |
matrix metalloproteinase | 5 |
innate response | 5 |
gastroenteritis virus | 5 |
covid pandemic | 5 |
damaged cells | 5 |
well documented | 5 |
psychological effects | 5 |
cell responses | 5 |
factor xii | 5 |
treat asthma | 5 |
immune memory | 5 |
per million | 5 |
tissue distribution | 5 |
increased levels | 5 |
activator inhibitor | 5 |
drinking water | 5 |
infectious conjunctivitis | 5 |
airway epithelial | 5 |
related siglecs | 5 |
renal transplant | 5 |
mesenteric fat | 5 |
insulin resistance | 5 |
cd expression | 5 |
prostatic hyperplasia | 5 |
reference sequence | 5 |
delivery systems | 5 |
antigen presentation | 5 |
worse outcomes | 5 |
inflammatory drugs | 5 |
human plasma | 5 |
current outbreak | 5 |
bacterial translocation | 5 |
inflammatory bowel | 5 |
expression may | 5 |
epigallocatechin gallate | 5 |
associated mortality | 5 |
metabolic diseases | 5 |
transplant recipients | 5 |
exponentially increases | 5 |
antioxidant activity | 5 |
cyps activity | 5 |
several clinical | 5 |
induced interstitial | 5 |
mortality due | 5 |
commonly used | 5 |
human endothelial | 5 |
allele frequency | 5 |
transmissible gastroenteritis | 5 |
aged garlic | 5 |
current pandemic | 5 |
pulmonary hypertension | 5 |
may increase | 5 |
synthase kinase | 5 |
controlled hypothermia | 4 |
statistically significant | 4 |
hypothesis will | 4 |
pulmonary inflammatory | 4 |
improves survival | 4 |
antibody production | 4 |
systemic oxidant | 4 |
metalloproteinase inducer | 4 |
specific adaptive | 4 |
may drive | 4 |
protective role | 4 |
camp levels | 4 |
emergency department | 4 |
recombinant human | 4 |
potential treatment | 4 |
superoxide production | 4 |
drug metabolism | 4 |
thereby decreasing | 4 |
termed coronavirus | 4 |
bcg vaccine | 4 |
short term | 4 |
aat administered | 4 |
natural origin | 4 |
patients develop | 4 |
physiological mechanisms | 4 |
different phenotypes | 4 |
new idea | 4 |
infection via | 4 |
coronavirus pandemic | 4 |
grape seed | 4 |
iv method | 4 |
activity may | 4 |
membrane biophysics | 4 |
associated acute | 4 |
induced obesity | 4 |
malaria infection | 4 |
people living | 4 |
different cell | 4 |
virus spread | 4 |
rs cc | 4 |
structural deviance | 4 |
case reports | 4 |
receptor alpha | 4 |
lymph nodes | 4 |
sore throat | 4 |
analysis based | 4 |
first two | 4 |
inflammatory process | 4 |
oxidative damage | 4 |
treatment options | 4 |
generation gcmaf | 4 |
oral epithelial | 4 |
human cyp | 4 |
receptor molecules | 4 |
coronavirus strain | 4 |
disease progresses | 4 |
potential targeted | 4 |
potential conflict | 4 |
ex vivo | 4 |
error term | 4 |
disease control | 4 |
genetic variation | 4 |
dependent rna | 4 |
promising results | 4 |
strenuous exercise | 4 |
body weight | 4 |
copper deficiency | 4 |
cardiac disease | 4 |
term infants | 4 |
relatively lower | 4 |
significantly higher | 4 |
mechanisms involved | 4 |
online ahead | 4 |
superoxide anion | 4 |
particle size | 4 |
less susceptible | 4 |
antiviral state | 4 |
projection models | 4 |
coronavirus receptor | 4 |
icu stay | 4 |
coagulation abnormalities | 4 |
infections compared | 4 |
cellular level | 4 |
hepatic cyp | 4 |
entry via | 4 |
oxidant chloramine | 4 |
close contacts | 4 |
healthy controls | 4 |
sirt activity | 4 |
male sex | 4 |
prone posturing | 4 |
humoral immunity | 4 |
coagulation factors | 4 |
multiple viral | 4 |
key molecule | 4 |
primary factor | 4 |
molecular mechanism | 4 |
helper cells | 4 |
human pulmonary | 4 |
severe endothelial | 4 |
zinc supplementation | 4 |
hospital death | 4 |
support corticosteroid | 4 |
vascular injury | 4 |
disseminated intravascular | 4 |
enhanced thrombosis | 4 |
vagal nerve | 4 |
reduced numbers | 4 |
inflammatory immune | 4 |
inanimate surfaces | 4 |
tissue eosinophilia | 4 |
blood cholesterol | 4 |
infections per | 4 |
may predispose | 4 |
human coronaviruses | 4 |
risk assessment | 4 |
creatine kinase | 4 |
genomic sequence | 4 |
risk groups | 4 |
cell interaction | 4 |
controlled clinical | 4 |
proinflammatory cytokine | 4 |
th century | 4 |
hypoxia inducible | 4 |
reducing sugars | 4 |
induced activation | 4 |
metabolic disorders | 4 |
possible role | 4 |
similar results | 4 |
health measures | 4 |
antitrypsin deficiency | 4 |
health consequences | 4 |
protein levels | 4 |
glioma tumorogenesis | 4 |
protease activity | 4 |
various countries | 4 |
asymptomatic infections | 4 |
visceral fat | 4 |
preliminary results | 4 |
ang i | 4 |
hepatic cyps | 4 |
coronavirus oc | 4 |
probably due | 4 |
eastern flank | 4 |
key step | 4 |
atopic dermatitis | 4 |
artery disease | 4 |
cd hla | 4 |
vascular disease | 4 |
current literature | 4 |
camp signalling | 4 |
may worsen | 4 |
times higher | 4 |
cyps expression | 4 |
poorly understood | 4 |
ace shedding | 4 |
transforming growth | 4 |
natural course | 4 |
aberrant ras | 4 |
emergency response | 4 |
also expressed | 4 |
anticoagulant protein | 4 |
model predicts | 4 |
local inflammation | 4 |
positive rate | 4 |
inflammatory diseases | 4 |
treating covid | 4 |
older age | 4 |
diarrhea virus | 4 |
adenosine receptor | 4 |
local innate | 4 |
portal vein | 4 |
without affecting | 4 |
epoxide reductase | 4 |
lipid droplet | 4 |
march th | 4 |
center study | 4 |
ace inhibition | 4 |
nalp inflammasome | 4 |
resident doctors | 4 |
tb infection | 4 |
porcine epidemic | 4 |
neuromodulation support | 4 |
generally accepted | 4 |
strength solution | 4 |
host factors | 4 |
positive cases | 4 |
cell adhesion | 4 |
early transmission | 4 |
cysteinyl leukotriene | 4 |
responses may | 4 |
adenosine monophosphate | 4 |
cholesterol level | 4 |
primary human | 4 |
enzyme ii | 4 |
box protein | 4 |
hyaline membrane | 4 |
effective antiviral | 4 |
final number | 4 |
predispose individuals | 4 |
severe patients | 4 |
deceased patients | 4 |
may antagonize | 4 |
strong association | 4 |
damage induced | 4 |
terminal site | 4 |
ncov lung | 4 |
times daily | 4 |
pulmonary pathology | 4 |
cell activity | 4 |
low vitamin | 4 |
water content | 4 |
novel human | 4 |
term sequelae | 4 |
pulmonary response | 4 |
viral proteins | 4 |
syndrome seen | 4 |
recent reports | 4 |
natural resistance | 4 |
degradation products | 4 |
current knowledge | 4 |
remain unknown | 4 |
virus entry | 4 |
experimental data | 4 |
develop severe | 4 |
eye region | 4 |
adhesion molecules | 4 |
acid oxidation | 4 |
sirt activators | 4 |
atp depletion | 4 |
clinical findings | 4 |
study found | 4 |
settling velocity | 4 |
lipid enveloped | 4 |
carbon monoxide | 4 |
disease covid | 4 |
response syndrome | 4 |
systemic circulation | 4 |
human epithelial | 4 |
increased expression | 4 |
hypotheses journal | 4 |
rare earth | 4 |
particle deposition | 4 |
antiviral response | 4 |
congestive heart | 4 |
antithrombotic effects | 4 |
chronic pulmonary | 4 |
vaccine development | 4 |
tuberculosis infection | 4 |
immunoglobulin superfamily | 4 |
signal transduction | 4 |
controlled study | 4 |
cardiovascular risk | 4 |
mental health | 4 |
major role | 4 |
coronary heart | 4 |
ffp masks | 4 |
black people | 4 |
like syndrome | 4 |
analysis showed | 4 |
birds eye | 4 |
rat model | 4 |
engineered human | 4 |
increased surface | 4 |
cell count | 4 |
volcanic gases | 4 |
severe influenza | 4 |
patient infected | 4 |
nm diameter | 4 |
black death | 4 |
environmental conditions | 4 |
current covid | 4 |
membrane displayed | 4 |
load per | 4 |
influenza vaccines | 4 |
influenza infections | 4 |
autopsy series | 4 |
hiv infection | 4 |
rhythms may | 4 |
nets formation | 4 |
potential conflicts | 4 |
epidemiological characteristics | 4 |
small droplets | 4 |
also contribute | 4 |
intestinal epithelial | 4 |
th responses | 4 |
physiologically based | 4 |
human clinical | 4 |
respiratory viruses | 4 |
will also | 4 |
less likely | 4 |
simulating control | 4 |
studies indicate | 4 |
converts angiotensin | 4 |
explanatory variables | 4 |
promising agent | 4 |
agonist fenofibrate | 4 |
hmgb release | 4 |
mrna expression | 4 |
epidemic diarrhea | 4 |
high ionic | 4 |
current situation | 4 |
united kingdom | 4 |
induced liver | 4 |
interstitial pneumonia | 4 |
medical hypotheses | 4 |
vaccination coverage | 4 |
chronic inflammation | 4 |
derived macrophage | 4 |
eliciting cell | 4 |
important risk | 4 |
increased intestinal | 4 |
central pituitary | 4 |
circulating cd | 4 |
intracellular viral | 4 |
positive patients | 4 |
survival benefit | 4 |
many people | 4 |
injurious pulmonary | 4 |
human hepatocytes | 4 |
therapeutic intervention | 4 |
functional food | 4 |
macrophage colony | 4 |
facial transmission | 4 |
existing drugs | 4 |
cellular energy | 4 |
prevent severe | 4 |
respiratory coronavirus | 4 |
direct antiviral | 4 |
antioxidative properties | 4 |
different specialties | 4 |
factor kappa | 4 |
feedback cycle | 4 |
also play | 4 |
low density | 4 |
therapeutic drug | 4 |
cell response | 4 |
many patients | 4 |
i suggest | 4 |
large amounts | 4 |
human serum | 4 |
soluble ace | 4 |
displayed ps | 4 |
via ace | 4 |
leading cause | 4 |
glucose levels | 4 |
pulmonary sarcoidosis | 4 |
secreted glycoprotein | 4 |
health workers | 4 |
aat may | 4 |
antibody response | 4 |
also reduced | 4 |
therapeutic use | 4 |
latin america | 4 |
inhaled vitamin | 4 |
three times | 4 |
thrombotic effects | 4 |
scientific community | 4 |
surgical mask | 4 |
transcutaneous non | 4 |
surfactant phospholipid | 4 |
administered dose | 4 |
national health | 4 |
therapeutic role | 4 |
chromosomal protein | 4 |
four hypotheses | 4 |
cultured rat | 4 |
fibrin degradation | 4 |
drug metabolizing | 4 |
protective effects | 4 |
tumor growth | 4 |
clinically relevant | 4 |
iv nac | 4 |
future studies | 4 |
phosphatidylcholine bilayers | 4 |
imaging findings | 4 |
viral pathogens | 4 |
cytokine profiles | 4 |
data suggest | 4 |
model saturated | 4 |
bowel disease | 4 |
effective vaccine | 4 |
i propose | 4 |
spike proteins | 4 |
mediated inflammation | 4 |
normal human | 4 |
disease conditions | 4 |
active faults | 4 |
recombinant hdef | 4 |
lessons learned | 4 |
disease course | 4 |
chronic periodontitis | 4 |
tissue ace | 4 |
may improve | 4 |
intravascular coagulation | 4 |
aerosol application | 4 |
empiric antibiotics | 4 |
yeast beta | 4 |
transcription factors | 4 |
fragment theory | 4 |
well understood | 4 |
bronchoalveolar lavage | 4 |
cns infections | 4 |
including sars | 4 |
box chromosomal | 4 |
intratracheal administration | 4 |
via activation | 4 |
different cyps | 4 |
initial alarm | 4 |
cytokine activity | 4 |
salivary glands | 4 |
allow us | 4 |
critical patients | 4 |
carbohydrate interaction | 4 |
antiviral agent | 4 |
well established | 4 |
induced inflammation | 4 |
increased oxidative | 4 |
bacillus calmette | 4 |
hiv replication | 4 |
antiphospholipid antibodies | 4 |
alveolar space | 4 |
inflammatory lung | 4 |
lavage fluid | 4 |
molecular dynamics | 4 |
activated macrophages | 4 |
reduced morbidity | 4 |
sunless tanning | 4 |
leptin receptor | 4 |
inhibits influenza | 4 |
health authorities | 4 |
responses induced | 4 |
viral activity | 4 |
esterified derivative | 4 |
reductase complex | 4 |
ionic strength | 4 |
emotional exhaustion | 4 |
novel treatment | 4 |
infection depend | 4 |
aerosol particles | 4 |
hospital admission | 4 |
age group | 4 |
treated patients | 4 |
group system | 4 |
critical illness | 4 |
treat covid | 4 |
bridge adaptive | 4 |
immunomodulatory properties | 4 |
per droplet | 4 |
fatal consequences | 4 |
healthy volunteers | 4 |
peripheral lymphatic | 4 |
lymphocyte ratio | 4 |
lower levels | 4 |
expression levels | 4 |
contributable variable | 4 |
named covid | 4 |
worse outcome | 4 |
fulminant acute | 4 |
atherosclerotic plaques | 4 |
polymerase chain | 4 |
inflammatory action | 4 |
nutritional deficiencies | 4 |
stromal cells | 4 |
factor xa | 4 |
repeated infections | 4 |
ethyl pyruvate | 4 |
related morbidity | 4 |
invasive vagal | 4 |
low occurrence | 4 |
muscle fibers | 4 |
infection date | 4 |
chain reaction | 4 |
known anti | 4 |
remain airborne | 4 |
membrane formation | 4 |
nadph oxidase | 4 |
antitrypsin inhibits | 4 |
nac may | 4 |
inflammasome inhibition | 4 |
based pharmacokinetic | 4 |
organ specific | 4 |
size distribution | 4 |
universal bcg | 4 |
neurological symptoms | 4 |
pulmonary embolism | 4 |
surfactant preparations | 4 |
sars pathogenesis | 4 |
mrna levels | 4 |
plasmodium falciparum | 4 |
factor ixa | 4 |
corticosteroid treatment | 4 |
replacement therapy | 4 |
surfactant dysfunction | 4 |
long time | 4 |
hypoxic pulmonary | 4 |
young patients | 4 |
siglec binding | 4 |
proposed mechanism | 4 |
multiorgan failure | 4 |
plasma concentrations | 4 |
two subunits | 4 |
pathophysiologic processes | 4 |
secretory phospholipase | 4 |
respiratory pathogens | 4 |
also associated | 4 |
epidemiological study | 3 |
safety data | 3 |
active metabolite | 3 |
one study | 3 |
host immunity | 3 |
pooled analysis | 3 |
influenza outbreaks | 3 |
intervention protocols | 3 |
might explain | 3 |
using anti | 3 |
tumor cells | 3 |
specific immune | 3 |
fibrin thrombi | 3 |
physiological changes | 3 |
pneumonia emergency | 3 |
defense mechanism | 3 |
superoxide anions | 3 |
indoor environments | 3 |
fiji image | 3 |
commercially available | 3 |
positively correlated | 3 |
endothelial inflammation | 3 |
markedly diminish | 3 |
study endothelial | 3 |
tenase complex | 3 |
covid infection | 3 |
novel corona | 3 |
health records | 3 |
epidermal growth | 3 |
state oxygen | 3 |
cumulative number | 3 |
also process | 3 |
testosterone replacement | 3 |
host antiviral | 3 |
community control | 3 |
reported worldwide | 3 |
highly pathogenic | 3 |
negative effects | 3 |
seminiferous tubule | 3 |
aii receptor | 3 |
significantly reduced | 3 |
low expression | 3 |
vaccination policy | 3 |
genetic susceptibility | 3 |
tight custom | 3 |
impaired vascular | 3 |
marine sponge | 3 |
surfactant lipids | 3 |
necrotic cells | 3 |
interests related | 3 |
protection equipment | 3 |
potent anti | 3 |
virus due | 3 |
journal homepage | 3 |
mesenteric lymph | 3 |
patients using | 3 |
immunosuppression therapy | 3 |
germ cells | 3 |
tobacco smokers | 3 |
significant risk | 3 |
etna volcano | 3 |
lung axis | 3 |
epub ahead | 3 |
membrane proteins | 3 |
large numbers | 3 |
open reading | 3 |
human hepatoma | 3 |
pulmonary manifestations | 3 |
normative data | 3 |
coronavirus diseases | 3 |
particularly prevalent | 3 |
effect observed | 3 |
scientific research | 3 |
aged years | 3 |
study suggested | 3 |
beneficial effect | 3 |
cigarette users | 3 |
receptor signaling | 3 |
total population | 3 |
uremic toxins | 3 |
healthy lung | 3 |
chemokine receptors | 3 |
age related | 3 |
activate cell | 3 |
new insights | 3 |
enzyme gene | 3 |
traditional formulation | 3 |
mediated immunity | 3 |
prospective cohort | 3 |
adverse remodelling | 3 |
using pseudomona | 3 |
signalling pathway | 3 |
bilayer membranes | 3 |
also show | 3 |
infectious bronchitis | 3 |
kappab activation | 3 |
autopsy cases | 3 |
least two | 3 |
clock genes | 3 |
undergone enhancements | 3 |
kidney injury | 3 |
known facts | 3 |
surfactant medications | 3 |
pao fio | 3 |
solution reduces | 3 |
lung surfactant | 3 |
antibodies may | 3 |
one possible | 3 |
male covid | 3 |
factors affecting | 3 |
vivo study | 3 |
advanced stages | 3 |
person transmission | 3 |
show increased | 3 |
stranded dna | 3 |
viral capsid | 3 |
levels decline | 3 |
ace may | 3 |
male patient | 3 |
double blind | 3 |
symptomatic patients | 3 |
cells including | 3 |
data presented | 3 |
myeloidderived suppressor | 3 |
genomic sequences | 3 |
real concern | 3 |
attenuates lung | 3 |
recent report | 3 |
without reduction | 3 |
bacterial sepsis | 3 |
lymphocytic choriomeningitis | 3 |
virus transmission | 3 |
soluble siglec | 3 |
supplemental oxygen | 3 |
promote th | 3 |
patients progress | 3 |
receptor blockade | 3 |
cd cd | 3 |
metabolic activity | 3 |
mandatory vaccines | 3 |
avian influenza | 3 |
clinical therapies | 3 |
chemical properties | 3 |
virus load | 3 |
experimental models | 3 |
creactive protein | 3 |
lymphatic drainage | 3 |
lymphatic systems | 3 |
induced production | 3 |
pulmonary alveolar | 3 |
complement system | 3 |
dose must | 3 |
inflammatory activity | 3 |
fatal covid | 3 |
current coronavirus | 3 |
might lead | 3 |
care providers | 3 |
aat response | 3 |
sodium channels | 3 |
vascular breach | 3 |
virucidal efficacy | 3 |
lowering drugs | 3 |
lung tissues | 3 |
tumour necrosis | 3 |
lung lesion | 3 |
grade fever | 3 |
specific igg | 3 |
reported cases | 3 |
sound biochemical | 3 |
life cycle | 3 |
sports medicine | 3 |
preventive measure | 3 |
infection ranges | 3 |
antiinflammatory effects | 3 |
vitro study | 3 |
clinically available | 3 |
sulfur dioxide | 3 |
human umbilical | 3 |
improving lung | 3 |
excellent safety | 3 |
oxidant amplification | 3 |
induced myopathy | 3 |
cresyl sulfate | 3 |
available evidence | 3 |
decrease elevated | 3 |
maximum oxygen | 3 |
medical conditions | 3 |
inpatient pregnant | 3 |
higher numbers | 3 |
species complex | 3 |
photodynamic therapy | 3 |
second messenger | 3 |
increases expression | 3 |
yellow fever | 3 |
strongly correlated | 3 |
might result | 3 |
cancer immunotherapy | 3 |
three minutes | 3 |
pg inhibits | 3 |
causal agents | 3 |
application form | 3 |
bl mice | 3 |
chinese center | 3 |
warmer weather | 3 |
capillary leak | 3 |
also pay | 3 |
journal pertain | 3 |
disease activity | 3 |
i herein | 3 |
reduce inflammation | 3 |
ion channel | 3 |
leukocyte recruitment | 3 |
spread across | 3 |
air temperature | 3 |
stat pathway | 3 |
infection covid | 3 |
large scale | 3 |
hepatic procoagulant | 3 |
like symptoms | 3 |
nih lays | 3 |
mers epidemic | 3 |
carry oxygen | 3 |
potent inhibitor | 3 |
viral conjunctivitis | 3 |
mysterious clots | 3 |
emerging infection | 3 |
partially responsible | 3 |
also stimulates | 3 |
covid wards | 3 |
plasmacytoid dendritic | 3 |
reports showed | 3 |
therapeutic options | 3 |
definitive version | 3 |
prevent infection | 3 |
therapeutic target | 3 |
inhibit activation | 3 |
cascade takes | 3 |
altitude inhabitants | 3 |
world countries | 3 |
primary care | 3 |
stage disease | 3 |
high rate | 3 |
preliminary report | 3 |
via bradykinin | 3 |
primary cultures | 3 |
prevent early | 3 |
lymphocyte proliferation | 3 |
southern italy | 3 |
risk stratification | 3 |
za zhi | 3 |
diminish pulmonary | 3 |
induced intestinal | 3 |
proven effective | 3 |
will undergo | 3 |
protected volume | 3 |
microbes infect | 3 |
pretreatment decreases | 3 |
lacking amount | 3 |
colleagues reported | 3 |
version will | 3 |
earth pneumoconiosis | 3 |
cover page | 3 |
actin filaments | 3 |
aecii cells | 3 |
previously reported | 3 |
larger droplets | 3 |
support choices | 3 |
old male | 3 |
pm exposure | 3 |
therapeutic regimen | 3 |
clinical implications | 3 |
increase intestinal | 3 |
respiratory treatments | 3 |
medical teams | 3 |
patient care | 3 |
explain variable | 3 |
dendriform pulmonary | 3 |
thrombotic incidences | 3 |
male germ | 3 |
specific effects | 3 |
old drug | 3 |
dr low | 3 |
african countries | 3 |
reaching consequences | 3 |
protein fragments | 3 |
marrow suppression | 3 |
type iii | 3 |
mortality among | 3 |
minimise disease | 3 |
vivo studies | 3 |
experiments using | 3 |
important hypothesis | 3 |
ventilatory support | 3 |
strand rna | 3 |
blood concentrations | 3 |
high binding | 3 |
also lead | 3 |
ongoing clinical | 3 |
antimalarial drugs | 3 |
biological functions | 3 |
bone lesions | 3 |
key player | 3 |
th phenotype | 3 |
microbiome derived | 3 |
days later | 3 |
custom made | 3 |
ace based | 3 |
times per | 3 |
good accuracy | 3 |
aberrant renin | 3 |
gastrointestinal manifestations | 3 |
administered via | 3 |
soluble tnf | 3 |
will help | 3 |
work received | 3 |
analyzed sars | 3 |
sodium hypochlorite | 3 |
induced acute | 3 |
radon measurements | 3 |
i interferonopathies | 3 |
foam cells | 3 |
thrombus formation | 3 |
hold potential | 3 |
metabolic rate | 3 |
phosphodiesterase inhibitor | 3 |
inflammatory factors | 3 |
adhesion molecule | 3 |
null women | 3 |
valid hypothesis | 3 |
cd cell | 3 |
dengue fever | 3 |
activated neutrophils | 3 |
rat liver | 3 |
cell loss | 3 |
essential compounds | 3 |
may well | 3 |
towards egfr | 3 |
human angiotensin | 3 |
give early | 3 |
high glucose | 3 |
whilst death | 3 |
polymorphonuclear leukocytes | 3 |
dose vka | 3 |
inhibit viral | 3 |
repurpose existing | 3 |
also induces | 3 |
oral application | 3 |
depleted state | 3 |
factor va | 3 |
hyaline membranes | 3 |
infected person | 3 |
tobacco leaves | 3 |
via molecular | 3 |
national natural | 3 |
magnesium deficiency | 3 |
will allow | 3 |
active tb | 3 |
current evidence | 3 |
acute cardiac | 3 |
autophagy pathway | 3 |
patients showed | 3 |
liver damage | 3 |
just like | 3 |
free survival | 3 |
immune systems | 3 |
small vessels | 3 |
redox balance | 3 |
additional copyediting | 3 |
clinical use | 3 |
cloak ps | 3 |
disease date | 3 |
rat stomachs | 3 |
immune activation | 3 |
bipolar disorder | 3 |
type diabetics | 3 |
severe novel | 3 |
cancer patients | 3 |
left ventricular | 3 |
seasonal influenza | 3 |
modern inhalation | 3 |
proteinase inhibitor | 3 |
conditions associated | 3 |
chloramine inhibits | 3 |
also accompanied | 3 |
essential component | 3 |
adam also | 3 |
assess whether | 3 |
related genes | 3 |
target cell | 3 |
mediated inflammatory | 3 |
pulmonary insult | 3 |
signaling cascade | 3 |
radon concentration | 3 |
activated factor | 3 |
secondary antibody | 3 |
immunopathological response | 3 |
errors may | 3 |
cytokinic storm | 3 |
potential usage | 3 |
direct endothelial | 3 |
pseudomonas aeruginosa | 3 |
multifunctional protein | 3 |
drug induced | 3 |
advanced age | 3 |
aerosol might | 3 |
infection causes | 3 |
new vaccine | 3 |
will prevent | 3 |
adverse outcomes | 3 |
nucleic acid | 3 |
deaths worldwide | 3 |
dd genotype | 3 |
induces ace | 3 |
new viral | 3 |
monocytes macrophages | 3 |
monocytic mdsc | 3 |
novel coronaviruses | 3 |
different studies | 3 |
ps cells | 3 |
induce gel | 3 |
airborne influenza | 3 |
moderate symptoms | 3 |
air pollutants | 3 |
inflammatory mediator | 3 |
declares covid | 3 |
receptor cd | 3 |
easily available | 3 |
physiological conditions | 3 |
long structural | 3 |
term follow | 3 |
poorly soluble | 3 |
potential drugs | 3 |
two groups | 3 |
bph treatment | 3 |
gain intracellular | 3 |
mediated cytokine | 3 |
enzyme inhibition | 3 |
indoxyl sulfate | 3 |
protein molecule | 3 |
fluidodynamical resistance | 3 |
provide support | 3 |
care professionals | 3 |
cellular receptor | 3 |
influenza infection | 3 |
respiratory function | 3 |
pulmonary protective | 3 |
viral effect | 3 |
surface area | 3 |
early visibility | 3 |
inflammatory disease | 3 |
conditions described | 3 |
severe pneumonia | 3 |
receptor axis | 3 |
significant protection | 3 |
serum vitamin | 3 |
rapidly spreading | 3 |
wakeup call | 3 |
pituitary lymphatic | 3 |
therapeutic application | 3 |
abnormal renal | 3 |
genetic analysis | 3 |
double ring | 3 |
will lead | 3 |
lung failure | 3 |
lower risk | 3 |
containing receptors | 3 |
resistant staphylococcus | 3 |
may serve | 3 |
oral administration | 3 |
coagulation components | 3 |
protein encoded | 3 |
deaths population | 3 |
age distribution | 3 |
organ pathology | 3 |
symptomatic relief | 3 |
treatment strategies | 3 |
observations made | 3 |
uncontrolled diabetes | 3 |
intracellular entry | 3 |
glass slide | 3 |
prothrombotic cascade | 3 |
renal dysfunction | 3 |
molecular biology | 3 |
reducing sars | 3 |
patients died | 3 |
regulated androgen | 3 |
inflammatory pathways | 3 |
mast cells | 3 |
airborne particles | 3 |
blood circulation | 3 |
infect dis | 3 |
elderly age | 3 |
studies suggest | 3 |
disrupted activation | 3 |
hypothesis provides | 3 |
respiratory capacity | 3 |
observed following | 3 |
particularly relevant | 3 |
inflammatory monocyte | 3 |
molecular weight | 3 |
cancer cells | 3 |
wuhan city | 3 |
ace imbalance | 3 |
relevant characteristics | 3 |
mechanism underlying | 3 |
pathogenic human | 3 |
surfactant activity | 3 |
ace gene | 3 |
human exposure | 3 |
neutrophil granulocytes | 3 |
response epidemiology | 3 |
moderate level | 3 |
limiting effects | 3 |
gastric mucosal | 3 |
inhibit tmprss | 3 |
studies also | 3 |
saturated phosphatidylcholine | 3 |
clinical practice | 3 |
patients diagnosed | 3 |
skin inflammation | 3 |
antagonist licensed | 3 |
specific funding | 3 |
circulating angiotensin | 3 |
turn activate | 3 |
possible association | 3 |
cause progression | 3 |
coronavirus entry | 3 |
reduces times | 3 |
target drug | 3 |
even better | 3 |
peroxide may | 3 |
infections may | 3 |
symptomatic infection | 3 |
pseudomona aeruginosa | 3 |
excessive immune | 3 |
potential benefits | 3 |
redox potential | 3 |
study clinical | 3 |
literature suggests | 3 |
explain many | 3 |
system enter | 3 |
novel hypothesis | 3 |
related infections | 3 |
peripheral lymphocyte | 3 |
aerosol transmission | 3 |
system cells | 3 |
chinese medicine | 3 |
coronavirus infected | 3 |
fibroblast proliferation | 3 |
ras status | 3 |
potential vaccines | 3 |
cellular protease | 3 |
nucleic acids | 3 |
hla types | 3 |
factor ix | 3 |
acid co | 3 |
spike receptor | 3 |
different respiratory | 3 |
pathways involved | 3 |
consciously check | 3 |
associated pneumonia | 3 |
please note | 3 |
using clinical | 3 |
exaggerated immune | 3 |
devastating infection | 3 |
basic diseases | 3 |
inner leaflets | 3 |
disease spectrum | 3 |
independent risk | 3 |
colostrum maf | 3 |
angiotensin peptides | 3 |
image analysis | 3 |
trials investigating | 3 |
high bioavailability | 3 |
disease outcomes | 3 |
neuroblastoma cells | 3 |
biological action | 3 |
disease outcome | 3 |
cytokine responses | 3 |
epithelial barrier | 3 |
coronavirus family | 3 |
peroxisome proliferatoractivated | 3 |
remains unclear | 3 |
microvascular injury | 3 |
high frequency | 3 |
might suppress | 3 |
com locate | 3 |
i hypothesized | 3 |
three chinese | 3 |
work proposes | 3 |
may bind | 3 |
virological studies | 3 |
nutritional support | 3 |
microvascular endothelial | 3 |
poor outcome | 3 |
cell counts | 3 |
high potential | 3 |
lung edema | 3 |
actively kept | 3 |
pilot study | 3 |
molecule may | 3 |
atmospheric particles | 3 |
montelukast molecule | 3 |
bone homeostasis | 3 |
different viruses | 3 |
oxidative species | 3 |
exact underlying | 3 |
human health | 3 |
binding pocket | 3 |
lungs will | 3 |
human subjects | 3 |
chest ct | 3 |
basigin cd | 3 |
found online | 3 |
lung alveolar | 3 |
vein endothelial | 3 |
prothrombinase complex | 3 |
derived toxins | 3 |
fully understood | 3 |
relative ace | 3 |
using ptx | 3 |
production via | 3 |
multiple associated | 3 |
vascular pathology | 3 |
ps exposure | 3 |
atpase oxidant | 3 |
immune exhaustion | 3 |
rheum palmatum | 3 |
administered orally | 3 |
deficiency leads | 3 |
tissue regeneration | 3 |
studies investigating | 3 |
gastrointestinal symptoms | 3 |
surface expression | 3 |
terminal glycosylation | 3 |
cardiogenic pulmonary | 3 |
tanning products | 3 |
association study | 3 |
testicular leydig | 3 |
infection control | 3 |
also due | 3 |
reduce mortality | 3 |
years ago | 3 |
significantly lower | 3 |
wuhan province | 3 |
renal disease | 3 |
increased tissue | 3 |
dysfunctional bridge | 3 |
selective review | 3 |
including several | 3 |
virus infectivity | 3 |
current global | 3 |
cardiac pathology | 3 |
considerations suggest | 3 |
human defensin | 3 |
significant attention | 3 |
defa gene | 3 |
system inhibitors | 3 |
vessel exposure | 3 |
hypothesis buried | 3 |
low personal | 3 |
surfactant phospholipids | 3 |
global threat | 3 |
global spread | 3 |
absolute number | 3 |
altitude areas | 3 |
future treatment | 3 |
brain barrier | 3 |
novel sars | 3 |
diminish reactive | 3 |
factor related | 3 |
acetylcysteine treatment | 3 |
allele may | 3 |
potential utility | 3 |
cc allele | 3 |
cytokine profile | 3 |
cultured cells | 3 |
genomewide association | 3 |
asymptomatic stage | 3 |
early identification | 3 |
sars outbreak | 3 |
umbilical vein | 3 |
ground state | 3 |
positive effect | 3 |
significant association | 3 |
patients receiving | 3 |
overactive immune | 3 |
multiple organs | 3 |
enhanced thrombogenicity | 3 |
ps molecules | 3 |
interferon gamma | 3 |
therapeutic implications | 3 |
severe side | 3 |
innate defense | 3 |
disrupted hpa | 3 |
cytokine generation | 3 |
situ evidence | 3 |
natural compounds | 3 |
profound loss | 3 |
active volcanoes | 3 |
urgent need | 3 |
directly related | 3 |
larger particles | 3 |
widely used | 3 |
intracerebral lymphatic | 3 |
hubei province | 3 |
adenosine triphosphate | 3 |
lethal cytokine | 3 |
streptococcus pneumoniae | 3 |
following infection | 3 |
negative conversion | 3 |
initial infection | 3 |
clinical management | 3 |
innate molecule | 3 |
locate mehy | 3 |
hypothesis also | 3 |
erythropoietin resistance | 3 |
infectious respiratory | 3 |
intracranial infections | 3 |
analysis sars | 3 |
wt mice | 3 |
final manuscript | 3 |
respiratory collapse | 3 |
hydroxychloroquine sulfate | 3 |
human peripheral | 3 |
rna interference | 3 |
therapy may | 3 |
severe coronavirus | 3 |
observed using | 3 |
infections caused | 3 |
strong interferon | 3 |
drug clearance | 3 |
vivo experiments | 3 |
cause severe | 3 |
health system | 3 |
deletion polymorphism | 3 |
causative agent | 3 |
bal fluids | 3 |
type diabetic | 3 |
immune evasion | 3 |
help manage | 3 |
oxygen flow | 3 |
mortality following | 3 |
factor activity | 3 |
repurposing strategy | 3 |
storm associated | 3 |
wuhan clinical | 3 |
often associated | 3 |
cancer progression | 3 |
also present | 3 |
sickle cell | 3 |
typical acute | 3 |
virus display | 3 |
hospital mortality | 3 |
critical event | 3 |
confers significant | 3 |
administering nih | 3 |
affect male | 3 |
respiratory epithelial | 3 |
pdf file | 3 |
phospholipid bilayers | 3 |
induced cytokine | 3 |
prone positioning | 3 |
environmental factors | 3 |
dead people | 3 |
harmful effects | 3 |
ards associated | 3 |
phase response | 3 |
hypothesis may | 3 |
healthy individuals | 3 |
experimental model | 3 |
hepatoma cells | 3 |
therapeutic strategy | 3 |
cells within | 3 |
hyperinflammatory stage | 3 |
immune effects | 3 |
strong differences | 3 |
human cell | 3 |
connective tissue | 3 |
biologically active | 3 |
virtual screening | 3 |
paper discusses | 3 |
toxic side | 3 |
drag force | 3 |
pragmatic solution | 3 |
inhibit neutrophil | 3 |
stage covid | 3 |
lining fluid | 3 |
undergo additional | 3 |
specific cd | 3 |
fecal calprotectin | 3 |
inflammatory injury | 3 |
confirmed covid | 3 |
therapeutic targets | 3 |
beetroot juice | 3 |
early anticoagulation | 3 |
soluble form | 3 |
endothelial protein | 3 |
clinical efficacy | 3 |
plasma vitamin | 3 |
inflammatory states | 3 |
potentially induce | 3 |
liver cell | 3 |
activity seen | 3 |
cellular redox | 3 |
nucleocapsid protein | 3 |
nasal spray | 3 |
uk patients | 3 |
also shown | 3 |
room temperature | 3 |
three cases | 3 |
multiple factors | 3 |
major cause | 3 |
potentially enhance | 3 |
human intestinal | 3 |
serum cholesterol | 3 |
extrapulmonary manifestations | 3 |
control study | 3 |
hybrid lipids | 3 |
dimer levels | 3 |
envelope glycoproteins | 3 |
dose required | 3 |
mesenteric lymphatics | 3 |
viruses like | 3 |
front line | 3 |
neutrophil adhesion | 3 |
especially respiratory | 3 |
pathophysiologic mechanisms | 3 |
genome replication | 3 |
acute kidney | 3 |
like protease | 3 |
lower absorption | 3 |
pulmonary perfusion | 3 |
clinical significance | 3 |
current understanding | 3 |
falciparum malaria | 3 |
supplementary data | 3 |
ace function | 3 |
important contribution | 3 |
already approved | 3 |
variable severity | 3 |
increase endothelial | 3 |
least seven | 3 |
times greater | 3 |
plant virus | 3 |
determine whether | 3 |
tissue repair | 3 |
suppress overactive | 3 |
adrenal axis | 3 |
markedly reduced | 3 |
genomic characterization | 3 |
different types | 3 |
side effect | 3 |
study characteristics | 3 |
national institutes | 3 |
cell type | 3 |
like endothelial | 3 |
pulmonary compliance | 3 |
smoking might | 3 |
protein mediates | 3 |
different viral | 3 |
whole blood | 3 |
asymptomatic patients | 3 |
pathogen causing | 3 |
final form | 3 |
viral envelope | 3 |
different mechanisms | 3 |
pulmonary ossification | 3 |
cascade generated | 3 |
three active | 3 |
patients often | 3 |
accelerated hydrogen | 3 |
published studies | 3 |
hereby declare | 3 |
microthrombi formation | 3 |
barr virus | 3 |
naive cd | 3 |
immune dysfunction | 3 |
associate sars | 3 |
peaked epidemic | 3 |
human blood | 3 |
legal disclaimers | 3 |
disease susceptibility | 3 |
factor alpha | 3 |
liver involvement | 3 |
inflammatory angiotensin | 3 |
deadly virus | 3 |
patients affected | 3 |
existent depleted | 3 |
treating physicians | 3 |
nonsynonymous mutations | 3 |
inflammatory conditions | 3 |
th response | 3 |
ibuprofen necessary | 3 |
channel activity | 3 |
great relevant | 3 |
cardiovascular system | 3 |
dengue virus | 3 |
regional topography | 3 |
normal hepatic | 3 |
placebo controlled | 3 |
multiple sclerosis | 3 |
enzyme protects | 3 |
coronavirus attachment | 3 |
antiviral responses | 3 |
several mechanisms | 3 |
reduced local | 3 |
leukocyte function | 3 |
osteoclast differentiation | 3 |
longitudinal characteristics | 3 |
subclinical nutritional | 3 |
significantly associated | 3 |
molecular level | 3 |
includes coronavirus | 3 |
neonatal outcomes | 3 |
low molecular | 3 |
possible mechanisms | 3 |
potential mechanisms | 3 |
prevention strategies | 3 |
advanced covid | 3 |
food may | 3 |
drainage differences | 3 |
multiorgan damage | 3 |
mouth disease | 3 |
high ace | 3 |
ibuprofen demonstrated | 3 |
injury leading | 3 |
inhaled hydroxychloroquine | 3 |
drug design | 3 |
causing respiratory | 3 |
mathematical model | 3 |
therapeutic interventions | 3 |
developing severe | 3 |
antiviral agents | 3 |
known whether | 3 |
lung imaging | 3 |
genes may | 3 |
cryptococcus gattii | 3 |
glycation products | 3 |
zinc intake | 3 |
results suggest | 3 |